Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell CarcinomaMartin H. Voss, Darren R. Feldman, William Lee et al.|Journal of Clinical Oncology|2016Cited by 85
Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.James J. Hsieh, Robert J. Motzer, David Chen et al.|Journal of Clinical Oncology|2015Cited by 26
Understanding the genomic underpinnings of metastatic chromophobe renal cell carcinoma.Jozefina Casuscelli, James J. Hsieh, Patricia Wang et al.|Journal of Clinical Oncology|2016Cited by 1
A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features.Martin H. Voss, Darren R. Feldman, Ying‐Bei Chen et al.|Journal of Clinical Oncology|2015Cited by 1